Relaunching an old drug: the potential role of bexarotene in neurodegenerative diseases

Journal of Neurology

Volumn 263, Issue 1, 2016, Pages 177-178

  Riancho, Javier ^a   Berciano, Maria T ^b   Berciano, Jose ^a   Lafarga, Miguel ^b  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; NEUROPROTECTIVE AGENT; RETINOIC ACID RECEPTOR; TETRALIN DERIVATIVE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LETTER; LOW DRUG DOSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; AGONISTS; ANIMAL; NEURODEGENERATIVE DISEASES;

ANIMALS; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; RECEPTORS, RETINOIC ACID; TETRAHYDRONAPHTHALENES;

EID: 84955692149     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-015-8004-0     Document Type: Letter

References (15)

1. Evans RM, Mangelsdorf DJ (2014) Nuclear receptors, RXR, and the big bang. Cell 157(1):255–266
2. Lane MA, Bailey SJ (2005) Role of retinoid signalling in the adult brain. Prog Neurobiol 75(4):275–293
3. Farol LT, Hymes KB (2004) Bexarotene: a clinical review. Expert Rev Anticancer Ther 4(2):180–188
4. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE et al (2012) ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335(6075):1503–1506
5. Fitz NF, Cronican AA, Lefterov I, Koldamova R (2013) Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”. Science 340(6135):924
6. Tesseur I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, Borgers M et al (2013) Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”. Science 340(6135):924
7. Price AR, Xu G, Siemienski ZB, Smithson LA, Borchelt DR, Golde TE et al (2013) Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”. Science 340(6135):924
8. Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, Ulrich J et al (2013) Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”. Science 340(6135):924
9. Landreth GE, Cramer PE, Lakner MM, Cirrito JR, Wesson DW, Brunden KR et al (2013) Response to comments on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”. Science 340(6135):924
10. Bomben V, Holth J, Reed J, Cramer P, Landreth G, Noebels J (2014) Bexarotene reduces network excitability in models of Alzheimer’s disease and epilepsy. Neurobiol Aging 35(9):2091–2095
11. Lefterov I, Schug J, Mounier A, Nam KN, Fitz NF, Koldamova R (2015) RNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment. Neurobiol Dis 82:132–140
12. Balducci C, Paladini A, Micotti E, Tolomeo D, La Vitola P, Grigoli E et al (2015) The continuing failure of bexarotene in Alzheimer’s disease mice. J Alzheimers Dis 46(2):471–482
13. O’Hare E, Jeggo R, Kim EM, Barbour B, Walczak JS, Palmer P et al (2016) Lack of support for bexarotene as a treatment for Alzheimer’s disease. Neuropharmacology 100:124–130
14. McFarland K, Spalding TA, Hubbard D, Ma JN, Olsson R, Burstein ES (2013) Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson’s disease. ACS Chem Neurosci 4(11):1430–1438
15. Riancho J, Ruiz-Soto M, Villagrá NT, Berciano J, Berciano MT, Lafarga M (2014) Compensatory motor neuron response to chromatolysis in the murine hSOD1 G93A model of amyotrophic lateral sclerosis. Front Cell Neurosci 8:346